
Quarterly report 2024-Q2
added 08-12-2024
Vapotherm Revenue 2011-2026 | VAPO
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Vapotherm
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 68.7 M | 66.8 M | 113 M | 126 M | 48.1 M | 42.4 M | 35.6 M | 30.1 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 126 M | 30.1 M | 66.3 M |
Quarterly Revenue Vapotherm
| 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 16.9 M | 19.1 M | - | 15.2 M | 16 M | 17.7 M | - | 13.5 M | 13 M | 21.6 M | - | 38.1 M | 20.6 M | 32.3 M | 40.9 M | 30.6 M | 35.2 M | 19.1 M | 13 M | 10.8 M | 12 M | 12.3 M | 11.7 M | 9.39 M | 10.6 M | 10.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 40.9 M | 9.39 M | 19.1 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Medical devices industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
AxoGen
AXGN
|
225 M | $ 32.67 | 5.42 % | $ 1.5 B | ||
|
Conformis
CFMS
|
62 M | - | - | $ 16.4 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
172 M | - | - | $ 1.77 B | ||
|
Acutus Medical
AFIB
|
7.16 M | - | -26.83 % | $ 2.62 M | ||
|
AdaptHealth Corp.
AHCO
|
3.24 B | $ 12.24 | 2.47 % | $ 1.65 B | ||
|
Cardiovascular Systems
CSII
|
236 M | - | 0.15 % | $ 844 M | ||
|
Allied Healthcare Products
AHPI
|
6.02 M | - | 3.58 % | $ 2.21 M | ||
|
ClearPoint Neuro
CLPT
|
37 M | $ 9.36 | 3.2 % | $ 265 M | ||
|
Dynatronics Corporation
DYNT
|
27.4 M | - | 14.99 % | $ 929 K | ||
|
Obalon Therapeutics, Inc.
OBLN
|
1.59 M | - | -5.86 % | $ 30.6 M | ||
|
Bruker Corporation
BRKR
|
3.37 B | $ 38.24 | 4.28 % | $ 5.7 K | ||
|
Second Sight Medical Products
EYES
|
1 K | - | -0.97 % | $ 54.4 M | ||
|
GBS
GBS
|
3.05 M | - | -0.57 % | $ 7.12 M | ||
|
Apollo Endosurgery
APEN
|
76.9 M | - | - | $ 475 M | ||
|
FONAR Corporation
FONR
|
97.6 M | $ 18.61 | 0.13 % | $ 122 M | ||
|
Electromed
ELMD
|
64 M | $ 24.41 | 2.89 % | $ 206 M | ||
|
Globus Medical
GMED
|
2.94 B | $ 91.72 | 1.91 % | $ 12.4 B | ||
|
EDAP TMS S.A.
EDAP
|
44.1 M | $ 3.34 | -1.82 % | $ 125 M | ||
|
CryoLife, Inc.
CRY
|
253 M | - | -4.14 % | $ 702 M | ||
|
Avinger
AVGR
|
7.65 M | - | -20.74 % | $ 369 K | ||
|
Helius Medical Technologies
HSDT
|
644 K | $ 1.89 | 3.28 % | $ 1.15 M | ||
|
Integra LifeSciences Holdings Corporation
IART
|
1.61 B | $ 9.62 | 3.11 % | $ 741 M | ||
|
Align Technology
ALGN
|
4 B | $ 178.59 | 7.02 % | $ 13.4 B | ||
|
Invacare Corporation
IVC
|
181 M | - | - | $ 24.7 M | ||
|
Axonics Modulation Technologies
AXNX
|
274 M | - | - | $ 3.31 B | ||
|
Integer Holdings Corporation
ITGR
|
1.85 B | $ 87.43 | 2.73 % | $ 3.04 B | ||
|
Aziyo Biologics
AZYO
|
12.3 M | - | 1.37 % | $ 20.5 M | ||
|
OrthoPediatrics Corp.
KIDS
|
236 M | $ 16.18 | 2.63 % | $ 380 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.25 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
41 M | - | 0.03 % | $ 1.58 B | ||
|
LivaNova PLC
LIVN
|
1.39 B | $ 64.67 | 1.78 % | $ 3.53 B | ||
|
Misonix, Inc.
MSON
|
62.5 M | - | - | $ 462 M | ||
|
LENSAR
LNSR
|
58.4 M | $ 5.67 | 0.71 % | $ 67.8 M | ||
|
Neovasc
NVCN
|
2.55 M | - | - | $ 111 M | ||
|
Medtronic PLC
MDT
|
33.5 B | $ 88.04 | 1.87 % | $ 113 B | ||
|
Butterfly Network
BFLY
|
82.1 M | $ 4.18 | 3.21 % | $ 885 M | ||
|
Myomo
MYO
|
40.9 M | $ 0.68 | -0.3 % | $ 28.5 M | ||
|
Intersect ENT, Inc.
XENT
|
80.6 M | - | - | $ 955 M | ||
|
Nevro Corp.
NVRO
|
409 M | - | - | $ 217 M | ||
|
Cytosorbents Corporation
CTSO
|
37.1 M | $ 0.64 | 4.94 % | $ 39.8 M | ||
|
BIOLASE
BIOL
|
49.2 M | - | -13.19 % | $ 166 K | ||
|
Delcath Systems
DCTH
|
85.2 M | $ 9.84 | 1.76 % | $ 352 M | ||
|
BioSig Technologies
BSGM
|
40 K | - | 37.08 % | $ 85.7 M | ||
|
Boston Scientific Corporation
BSX
|
20.1 B | $ 62.3 | 0.71 % | $ 92.2 B | ||
|
Alphatec Holdings
ATEC
|
764 M | $ 11.45 | 3.76 % | $ 1.72 B | ||
|
IRIDEX Corporation
IRIX
|
52.7 M | $ 1.14 | 10.68 % | $ 19.3 M | ||
|
CONMED Corporation
CNMD
|
1.37 B | $ 36.46 | 5.56 % | $ 1.13 B |